Phenotypic features of crohn's disease associated with failure of medical treatment

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 3, 2014, Pages

  Moran, Gordon W ^a,b,c   Dubeau, Marie France ^a,b   Kaplan, Gilaad G ^a,b   Yang, Hong ^b   Seow, Cynthia H ^a,b   Fedorak, Richard N ^d   Dieleman, Levinus A ^d   Barkema, Herman W ^a,b   Ghosh, Subrata ^a,b   Panaccione, Remo ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Disease Phenotype; IBD; Immune Suppression; Prognostic Factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE REGISTRY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; ILEUM; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PHENOTYPE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; THERAPY DELAY; TREATMENT RESPONSE; YOUNG ADULT;

DISEASE PHENOTYPE; IBD; IMMUNE SUPPRESSION; PROGNOSTIC FACTOR;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; ALBERTA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84893973969     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.026     Document Type: Article

References (42)

1. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54. e42; quiz e30.
2. Agrez M.V., Valente R.M., Pierce W., et al. Surgical history of Crohn's disease in a well-defined population. Mayo Clin Proc 1982, 57:747-752.
3. Cosnes J., Nion-Larmurier I., Beaugerie L., et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
4. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5:1430-1438.
5. Wolters F.L., Russel M.G., Sijbrandij J., et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 2006, 243:46-54.
6. Ramadas A.V., Gunesh S., Thomas G.A., et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
7. Binder V., Hendriksen C., Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985, 26:146-150.
8. Bernell O., Lapidus A., Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000, 231:38-45.
9. Frolkis A.D., Dykeman J., Negron M.E., et al. Cumulative incidence of first intestinal surgery in adult and pediatric Crohn's disease: a systematic review and meta-analysis. Gastroenterology 2012, 142. S-790.
10. Bernstein C.N., Loftus E.V., Ng S.C., et al. Hospitalisations and surgery in Crohn's disease. Gut 2012, 61:622-629.
11. Thia K.T., Sandborn W.J., Harmsen W.S., et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
12. Louis E., Collard A., Oger A.F., et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
13. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
15. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
16. Peyrin-Biroulet L., Oussalah A., Williet N., et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
17. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
18. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
19. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
20. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
21. Louis E., Michel V., Hugot J.P., et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003, 52:552-557.
22. Cosnes J., Bourrier A., Nion-Larmurier I., et al. Factors affecting outcomes in Crohn's disease over 15 years. Gut 2012, 61:1140-1145.
23. Weston L.A., Roberts P.L., Schoetz D.J., et al. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996, 39:841-846.
24. Louis E., Boverie J., Dewit O., et al. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007, 70:15-19.
25. Henriksen M., Jahnsen J., Lygren I., et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007, 42:602-610.
26. Henriksen M., Jahnsen J., Lygren I., et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN study). Scand J Gastroenterol 2006, 41:1037-1043.
27. Reinisch W., Wang Y., Oddens B.J., et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012, 35:568-576.
28. Schreiber S., Reinisch W., Colombel J., et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007, 132:A147.
29. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. quiz e10-1.
30. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
31. Lemann M., Cuillerier E., Bouhnik Y., et al. Azathioprine (AZA) for prevention of Crohn's recurrence after ileal or colonic resection. Gastroenterology 1996, 110:A948.
32. Hanauer S., Korelitz B., Rutgeerts P., et al. Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicentre trial. Gastroenterology 1998, 114:A1011.
33. Pearson D.C., May G.R., Fick G., et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000, 2:CD000067.
34. Prefontaine E., Sutherland L.R., Macdonald J.K., et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 1:CD000067.
35. Shental O., Tulchinsky H., Greenberg R., et al. Positive histological inflammatory margins are associated with increased risk for intra-abdominal septic complications in patients undergoing ileocolic resection for Crohn's disease. Dis Colon Rectum 2012, 55:1125-1130.
36. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
37. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
38. Kopylov U., Ben-Horin S., Zmora O., et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012, 18:2404-2413.
39. Peyrin-Biroulet L., Deltenre P., Ardizzone S., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009, 104:2089-2096.
40. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.e1. quiz 716.
41. Wolters F.L., Russel M.G., Sijbrandij J., et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006, 55:1124-1130.
42. Nunes T., Etchevers M.J., Merino O., et al. Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis 2013, 19:23-29.